Inhaled extended-release microparticles of heparin elicit improved pulmonary pharmacodynamics against antigen-mediated airway hyper-reactivity and inflammation

Journal of Controlled Release

Volumn 162, Issue 2, 2012, Pages 456-463

  Yildiz, Ayca ^a,b   John, Elinor ^a   Özsoy, Yildiz ^b   Araman, Ahmet ^b   Birchall, James C ^a   Broadley, Kenneth J ^a   Gumbleton, Mark ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Airway hyper reactivity; Asthma; Heparin; Lung pharmacodynamics; Nebulised aerosol; PLGA microparticles

Indexed keywords

AEROSOL PROPERTIES; AIRWAY INFLAMMATION; ASTHMA; CONTROLLED RELEASE; DOSING STRATEGY; EQUIVALENT DOSE; HEPARIN; HEPARIN SOLUTIONS; IN-VITRO; IN-VIVO; INHIBITORY EFFECT; LUNG INFLAMMATION; MICRO-PARTICLES; NEBULISATION; PHARMACODYNAMIC RESPONSE; PLGA MICROPARTICLES; POLY(D ,L-LACTIDE-CO- GLYCOLIDE); RESPIRATORY TRACT; THERAPEUTIC APPLICATION; TOTAL DOSE; WORK SUPPORT;

ANTIGENS; ATMOSPHERIC AEROSOLS; BIOLOGICAL ORGANS; PATHOLOGY; PHARMACODYNAMICS;

POLYSACCHARIDES;

ANTIGEN; HEPARIN; OVALBUMIN; POLYMER;

AIRWAY HYPERREACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTHMA; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG RELEASE; IN VIVO STUDY; LUNG FUNCTION; MALE; NEBULIZATION; NONHUMAN; PARTICLE SIZE; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY TRACT ALLERGY; SPRAY DRYING; TREATMENT RESPONSE;

ADMINISTRATION, INHALATION; ANIMALS; ANTIGENS; BRONCHIAL HYPERREACTIVITY; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; GUINEA PIGS; HEPARIN; LACTIC ACID; LUNG; MALE; NEBULIZERS AND VAPORIZERS; OVALBUMIN; PNEUMONIA; POLYGLYCOLIC ACID; SOLUTIONS;

EID: 84865318347     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2012.07.008     Document Type: Article

References (50)

1. A.M. Dvorak, and E.S. Morgan Ribonuclease-gold ultrastructural localization of heparin in isolated human lung mast cells stimulated to undergo anaphylactic degranulation and recovery in vitro Clin. Exp. Allergy 29 1999 1118 1128
2. D.J. Tyrell, S. Kilfeather, and C.P. Page Therapeutic uses of heparin beyond its traditional role as an anticoagulant Trends Pharmacol. Sci. 16 1995 198 204
3. E. Young The anti-inflammatory effects of heparin and related compounds Thromb. Res. 122 2008 743 752
4. R. Lever, and C.P. Page Novel drug development opportunities for heparin Nat. Rev. Drug Discov. 1 2002 140 148
5. Z. Diamant, and C.P. Page Heparin and related molecules as a new treatment for asthma Pulm. Pharmacol. Ther. 13 2000 1 4
6. R. Lever, and C. Page Glycosaminoglycans, airways inflammation and bronchial hyperresponsiveness Pulm. Pharmacol. Ther. 14 2001 249 254
7. E.A. Seeds, and C.P. Page Heparin inhibits allergen-induced eosinophil infiltration into guinea-pig lung via a mechanism unrelated to its anticoagulant activity Pulm. Pharmacol. Ther. 14 2001 111 119
8. T. Ahmed, J. Ungo, M. Zhou, and C. Campo Inhibition of allergic late airway responses by inhaled heparin-derived oligosaccharides J. Appl. Physiol. 88 2000 1721 1729
9. C. Campo, J.F. Molinari, J. Ungo, and T. Ahmed Molecular-weight-dependent effects of nonanticoagulant heparins on allergic airway responses J. Appl. Physiol. 86 1999 549 557
10. J.M. Preuss, and C.P. Page Effect of heparin on antigen-induced airway responses and pulmonary leukocyte accumulation in neonatally immunized rabbits Br. J. Pharmacol. 129 2000 1585 1596
11. M. Sasaki, C.M. Herd, and C.P. Page Effect of heparin and a low-molecular weight heparinoid on PAF-induced airway responses in neonatally immunized rabbits Br. J. Pharmacol. 110 1993 107 112
12. T. Ahmed, W.M. Abraham, and J. D'Brot Effects of inhaled heparin on immunologic and nonimmunologic bronchoconstrictor responses in sheep Am. Rev. Respir. Dis. 145 1992 566 570
13. T. Ahmed, C. Campo, M.K. Abraham, J.F. Molinari, W.M. Abraham, D. Ashkin, T. Syriste, L.O. Andersson, and C.M. Svahn Inhibition of antigen-induced acute bronchoconstriction, airway hyperresponsiveness, and mast cell degranulation by a nonanticoagulant heparin: comparison with a low molecular weight heparin Am. J. Respir. Crit. Care Med. 155 1997 1848 1855
14. E.A. Seeds, A.P. Horne, D.J. Tyrrell, and C.P. Page The effect of inhaled heparin and related glycosaminoglycans on allergen-induced eosinophil infiltration in guinea-pigs Pulm. Pharmacol. 8 1995 97 105
15. Z. Diamant, M.C. Timmers, H. van der Veen, C.P. Page, F.J. van der Meer, and P.J. Sterk Effect of inhaled heparin on allergen-induced early and late asthmatic responses in patients with atopic asthma Am. J. Respir. Crit. Care Med. 153 1996 1790 1795
16. A.M. Fal, J. Miecielica, M. Krasnowska, W. Medrala, J. Kuryszko, and J. Malolepszy Influence of long-term low molecular weight heparin nebulization on selected clinical parameters and course of allergic inflammation in patients with bronchial asthma Pol. Arch. Med. Wewn. 106 2001 1121 1129
17. S.D. Bowler, S.M. Smith, and P.S. Lavercombe Heparin inhibits the immediate response to antigen in the skin and lungs of allergic subjects Am. Rev. Respir. Dis. 147 1993 160 163
18. J. Garrigo, I. Danta, and T. Ahmed Time course of the protective effect of inhaled heparin on exercise-induced asthma Am. J. Respir. Crit. Care Med. 153 1996 1702 1707
19. T. Ahmed, J. Garrigo, and I. Danta Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin N. Engl. J. Med. 329 1993 90 95
20. T. Ahmed, B.J. Gonzalez, and I. Danta Prevention of exercise-induced bronchoconstriction by inhaled low-molecular-weight heparin Am. J. Respir. Crit. Care Med. 160 1999 576 581
21. I. Stelmach, J. Jerzynska, W. Stelmach, P. Majak, A. Brzozowska, P. Gorski, and P. Kuna The effect of inhaled heparin on airway responsiveness to histamine and leukotriene D4 Allergy Asthma Proc. 24 2003 59 65
22. R. Polosa, S. Magri, C. Vancheri, F. Armato, G. Santonocito, A. Mistretta, and N. Crimi Time course of changes in adenosine 5′- monophosphate airway responsiveness with inhaled heparin in allergic asthma J. Allergy Clin. Immunol. 99 1997 338 344
23. F.A. Oyarzun-Ampuero, J. Brea, M.I. Loza, M.J. Alonso, and D. Torres A potential nanomedicine consisting of heparin-loaded polysaccharide nanocarriers for the treatment of asthma Macromol. Biosci. 12 2012 176 183
24. F.A. Oyarzun-Ampuero, J. Brea, M.I. Loza, D. Torres, and M.J. Alonso Chitosan-hyaluronic acid nanoparticles loaded with heparin for the treatment of asthma Int. J. Pharm. 381 2009 122 129
25. I. Pavord, T. Mudassar, J. Bennett, P. Wilding, and A. Knox The effect of inhaled heparin on bronchial reactivity to sodium metabisulphite and methacholine in patients with asthma Eur. Respir. J. 9 1996 217 219
26. L. Nilsson, C. Peterson, P. Venge, J.W. Borowiec, and S. Thelin Eosinophil granule proteins in cardiopulmonary bypass with and without heparin coating Ann. Thorac. Surg. 59 1995 713 716
27. M.S. Sy, E. Schneeberger, R. McCluskey, M.I. Greene, R.D. Rosenberg, and B. Benacerraf Inhibition of delayed-type hypersensitivity by heparin depleted of anticoagulant activity Cell. Immunol. 82 1983 23 32
28. E. Ragazzi, and A. Chinellato Heparin: pharmacological potentials from atherosclerosis to asthma Gen. Pharmacol. 26 1995 697 701
29. M. Frieri, and D.D. Metcalfe Analysis of the effect of mast cell granules on lymphocyte blastogenesis in the absence and presence of mitogens: identification of heparin as a granule-associated suppressor factor J. Immunol. 131 1983 1942 1948
30. J.R. Guyton, R.D. Rosenberg, A.W. Clowes, and M.J. Karnovsky Inhibition of rat arterial smooth muscle cell proliferation by heparin. In vivo studies with anticoagulant and nonanticoagulant heparin Circ. Res. 46 1980 625 634
31. S.A. Kilfeather, S. Tagoe, A.C. Perez, K. Okona-Mensa, R. Matin, and C.P. Page Inhibition of serum-induced proliferation of bovine tracheal smooth muscle cells in culture by heparin and related glycosaminoglycans Br. J. Pharmacol. 114 1995 1442 1446
32. H. Danahay, and K.J. Broadley Effects of inhibitors of phosphodiesterase, on antigen-induced bronchial hyperreactivity in conscious sensitized guinea-pigs and airway leukocyte infiltration Br. J. Pharmacol. 120 1997 289 297
33. T.J. Toward, and K.J. Broadley Early and late bronchoconstrictions, airway hyper-reactivity, leucocyte influx and lung histamine and nitric oxide after inhaled antigen: effects of dexamethasone and rolipram Clin. Exp. Allergy 34 2004 91 102
34. P. Giunchedi, B. Conti, I. Genta, U. Conte, and G. Puglisi Emulsion spray-drying for the preparation of albumin-loaded PLGA microspheres Drug Dev. Ind. Pharm. 27 2001 745 750
35. S.R. Gundry, M.D. Klein, R.A. Drongowski, and M.M. Kirsh Clinical evaluation of a new rapid heparin assay using the dye azure A Am. J. Surg. 148 1984 191 194
36. D.J. Finney Probit Analysis: A Statistical Treatment of the Signoid Response Curve 2009 Cambridge University Press Cambridge UK
37. N. Smith, and K.J. Broadley Optimisation of the sensitisation conditions for an ovalbumin challenge model of asthma Int. Immunopharmacol. 7 2007 183 190
38. D.A. Griffiths-Johnson, P.J. Nicholls, and M. McDermott Measurement of specific airway conductance in guinea pigs. A noninvasive method J. Pharmacol. Methods 19 1988 233 242
39. P. Giunchedi, E. Gavini, G. Bonacucina, and G.F. Palmieri Tabletted polylactide microspheres prepared by a w/o emulsion-spray drying method J. Microencapsul. 17 2000 711 720
40. D.B. Jacoby, G.J. Gleich, and A.D. Fryer Human eosinophil major basic protein is an endogenous allosteric antagonist at the inhibitory muscarinic M2 receptor J. Clin. Invest. 91 1993 1314 1318
41. P. Venge Serum measurements of eosinophil cationic protein (ECP) in bronchial asthma Clin. Exp. Allergy 23 Suppl. 2 1993 3 7 (discussion 15-22)
42. W. Domej, G. Schwaberger, G.P. Tilz, Z. Foldes-Papp, U. Demel, J. Lang, and S.P. von Duvillard Prolonged endurance challenge at moderate altitude: effect on serum eosinophil cationic protein, eosinophil dynamics, and lung function Chest 121 2002 1111 1116
43. P. Venge, and J. Bystrom Eosinophil cationic protein (ECP) Int. J. Biochem. Cell Biol. 30 1998 433 437
44. T. Yang, A. Hussain, S. Bai, I.A. Khalil, H. Harashima, and F. Ahsan Positively charged polyethylenimines enhance nasal absorption of the negatively charged drug, low molecular weight heparin J. Control. Release 115 2006 289 297
45. H. Yamamoto, Y. Kuno, S. Sugimoto, H. Takeuchi, and Y. Kawashima Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions J. Control. Release 102 2005 373 381
46. B. Burrows, F.M. Hasan, R.A. Barbee, M. Halonen, and M.D. Lebowitz Epidemiologic observations on eosinophilia and its relation to respiratory disorders Am. Rev. Respir. Dis. 122 1980 709 719
47. C. Agusti, K. Takeyama, L.O. Cardell, I. Ueki, J. Lausier, Y.P. Lou, and J.A. Nadel Goblet cell degranulation after antigen challenge in sensitized guinea pigs. Role of neutrophils Am. J. Respir. Crit. Care Med. 158 1998 1253 1258
48. I. Stelmach, J. Jerzynska, M. Bobrowska, A. Brzozowska, P. Majak, and P. Kuna The effect of inhaled heparin on airway responsiveness to metacholine in asthmatic children Pol. Arch. Med. Wewn. 106 2001 567 572
49. B. Tutluoglu, N. Gurbuz, S. Atis, S. Abanozlu, R. Ibis, and A. Kanik Effects of heparin on hypertonic potassium chloride-induced bronchoconstriction Ann. Pharmacother. 35 2001 1161 1165
50. C.M. Tranfa, A. Vatrella, R. Parrella, G. Pelaia, F. Bariffi, and S.A. Marsico Effect of inhaled heparin on water-induced bronchoconstriction in allergic asthmatics Eur. J. Clin. Pharmacol. 57 2001 5 9